The funds will be used for scaling up the product offering and adding more skill training content to their library
MedisimVR, a med-tech company working in the field of healthcare simulation, has raised Rs 3.5 crore in a Pre-Series A round led by Inflection Point Ventures. The round saw participation from Chennai Angels and Jana Balasubramaniam (MedTech investor). The funds raised will be used for scaling up their product offering and adding more skill training content to their library.
MediSimVR aims to make comprehensive medical training accessible and affordable across the world through the current offerings which include procedural simulation, virtual patient simulation and clinical education. They have been able to onboard almost 500 medical students in the last four months.
Vinay Bansal, Founder & CEO, Inflection Point Ventures says, “As the pandemic continues to trigger medical innovations both in vaccines and use of tech in health care. 2020 saw the emergence of tele-medicines and tele consultations. MediSimVR has understood this need for the healthcare industry to move one notch higher and adapt to new-age training technology for skilling medical students and healthcare professionals alike. Their simulation skill training programme, is where one can practice surgical training, encounter virtual patients scenarios, evaluate the learning metrics which will help the medical fraternity immensely. We find MediSimVR as a purpose-driven brand in addition to being a disruptive business idea.”
The Key product offered by MediSimVR is the virtual reality-based skill training platform, that covers all the skills required in the MBBS curriculum. Some of the other features include performance analytics and evaluation metrics to better assess the learning pattern and competency.
Sabarish Chandrasekaran, Co-Founder & CEO, MedisimVR, says, “The future healthcare workforce of India needs a futuristic training methodology and an alignment among visionary entities for rapid scaling up. At MediSimVR, we are excited to partner with IPV as we embark on this journey of change.”
